Abstract:
The study was aimed to assess the impact of bleomycine on the myocard.
The clinical case is presented by the male patient I. (DOB: 1978), receiveing bleomycine for testic
cancer. The ultrasound echocardioscopic tests were out on the Imagic Agile (USA) apparatus.
Scintigraphy with the early (30 min) and delayed uptake of Tc99 by the myocardium (3 hours) were
assessed as well. MRI of the heart was conducted on Siemens Avanto 1.5T MRI scanner. Philips
intellispace Portal 9.0 Cardiac Analyzis package was used for the assessment of functional parameters.
Subclinical changes in the myocardium were detected after the administration of bleomycine. Thus
its cardiotoxicity could be underestimated.
All human studies were conducted in compliance with the rules of the Helsinki Declaration of the
World Medical Association "Ethical principles of medical research with human participation as an object
of study". Informed consent was obtained from all participants.